Riboflavin for Migraine Prevention: The 400 mg Protocol

← Back to articles

Sensitive populations: This article references pediatric. Always confirm any supplement change with your child's pediatrician before starting — dosing, contraindications, and risk profile shift in these groups.

The mitochondrial hypothesis

People with migraine show signs of mild mitochondrial dysfunction: reduced ATP turnover and higher lactate on magnetic-resonance spectroscopy in some studies, and a higher prevalence of certain mitochondrial DNA variants. Riboflavin is the precursor to flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), cofactors in oxidative phosphorylation. The 400 mg/day dose is roughly 300 times the RDA and is intended to push flavin-dependent enzyme activity higher, not to correct dietary deficiency.

The Schoenen trial

The pivotal 1998 randomised controlled trial by Schoenen and colleagues randomised 55 migraine patients to 400 mg/day riboflavin or placebo for 3 months. Riboflavin was significantly better than placebo at reducing attack frequency (p=0.005) and headache days (p=0.012). The "responder" rate — patients whose attacks fell by at least 50% — was 59% on riboflavin versus 15% on placebo, giving a number-needed-to-treat of about 2.3 (Schoenen 1998; PMID 9484373; DOI 10.1212/wnl.50.2.466).

Subsequent evidence and guidelines

A systematic review of 11 clinical trials published over the next two decades reported a consistent positive effect in adults at 400 mg/day, with mixed and weaker effects in children and adolescents and no benefit when riboflavin was added to placebo-controlled combination products (Thompson 2017; PMID 28485121; DOI 10.1111/jcpt.12548). The American Academy of Neurology and American Headache Society guideline classifies riboflavin as Level B (probably effective) for episodic migraine prevention — the same tier as magnesium, feverfew (MIG-99), and several NSAIDs. Butterbur (Petasites) was Level A in that 2012 guideline, but the AHS later withdrew its recommendation because of unregulated pyrrolizidine-alkaloid hepatotoxicity in commercial products. Coenzyme Q10 sits at Level C (possibly effective) (Holland 2012; PMID 22529203; DOI 10.1212/WNL.0b013e3182535d0c).

Practical notes

Expect to give it 2–3 full months before judging the response. The only common side effect is bright fluorescent-yellow urine from excretion of excess riboflavin — harmless but startling. There are essentially no drug interactions and no dose-related toxicity, and the 400 mg/day dose is well above the RDA (1.3 mg) so it's only practical via supplementation. Riboflavin is sometimes used in combination with 400–600 mg magnesium and 100–300 mg coenzyme Q10 as a "mitochondrial trio," but the trial evidence for the combination is weaker than for the single agents and additivity hasn't been formally established.